Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2021)
Historic Income from Continuing Operations for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to -$25.5 million.
- Black Diamond Therapeutics' Income from Continuing Operations fell 1624.79% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.8 million, marking a year-over-year decrease of 7469.29%. This contributed to the annual value of -$123.4 million for FY2021, which is 8832.29% down from last year.
- As of Q4 2021, Black Diamond Therapeutics' Income from Continuing Operations stood at -$25.5 million, which was down 1624.79% from -$34.6 million recorded in Q3 2021.
- Black Diamond Therapeutics' Income from Continuing Operations' 5-year high stood at -$3.0 million during Q4 2018, with a 5-year trough of -$34.6 million in Q3 2021.
- Moreover, its 4-year median value for Income from Continuing Operations was -$13.5 million (2020), whereas its average is -$16.0 million.
- In the last 5 years, Black Diamond Therapeutics' Income from Continuing Operations crashed by 23530.33% in 2020 and then plummeted by 1624.79% in 2021.
- Over the past 4 years, Black Diamond Therapeutics' Income from Continuing Operations (Quarter) stood at -$3.0 million in 2018, then crashed by 225.15% to -$9.9 million in 2019, then tumbled by 121.42% to -$21.9 million in 2020, then decreased by 16.25% to -$25.5 million in 2021.
- Its Income from Continuing Operations stands at -$25.5 million for Q4 2021, versus -$34.6 million for Q3 2021 and -$33.8 million for Q2 2021.